Regeneron Pharmaceuticals Inc. (REGN)’s Financial Results Comparing With Rubius Therapeutics Inc. (NASDAQ:RUBY)

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Rubius Therapeutics Inc. (NASDAQ:RUBY) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 373 1.96 81.35M 18.21 20.45
Rubius Therapeutics Inc. 10 0.00 33.45M -1.85 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Regeneron Pharmaceuticals Inc. and Rubius Therapeutics Inc.


Table 2 shows Regeneron Pharmaceuticals Inc. and Rubius Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 21,791,540.54% 22.3% 16.6%
Rubius Therapeutics Inc. 319,179,389.31% -41.3% -32.6%


4 and 3.5 are the respective Current Ratio and a Quick Ratio of Regeneron Pharmaceuticals Inc. Its rival Rubius Therapeutics Inc.’s Current and Quick Ratios are 9.8 and 9.8 respectively. Rubius Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Regeneron Pharmaceuticals Inc.

Analyst Ratings

The table delivered features the ratings and recommendations for Regeneron Pharmaceuticals Inc. and Rubius Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 5 1 2.17
Rubius Therapeutics Inc. 1 0 2 2.67

Regeneron Pharmaceuticals Inc.’s downside potential currently stands at -8.24% and an $358.57 consensus price target. Rubius Therapeutics Inc. on the other hand boasts of a $12.33 consensus price target and a 31.31% potential upside. Based on the analysts view we can conclude, Rubius Therapeutics Inc. is looking more favorable than Regeneron Pharmaceuticals Inc.

Institutional and Insider Ownership

The shares of both Regeneron Pharmaceuticals Inc. and Rubius Therapeutics Inc. are owned by institutional investors at 73.8% and 91.97% respectively. Regeneron Pharmaceuticals Inc.’s share owned by insiders are 19.4%. Comparatively, Rubius Therapeutics Inc. has 2.6% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. 0.88% 14.72% 33.43% 22.35% -2.47% -0.33%
Rubius Therapeutics Inc. 37.92% 4.02% 11.91% -26.96% -49.98% -33.96%

For the past year Regeneron Pharmaceuticals Inc.’s stock price has smaller decline than Rubius Therapeutics Inc.


Regeneron Pharmaceuticals Inc. beats on 8 of the 13 factors Rubius Therapeutics Inc.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.